Schizophrenia Clinical Trials in New York

Showing 41-60 of 182 trials

CVN058 Effect on Mismatch Negativity in Schizophrenics

NCT03669250

This is a phase 1, double-blind, placebo-controlled, 3 period cross-over study to evaluate CVN058 target engagement by measuring auditory evoked potential mismatch negativity (MMN) downstream to 5-hydroxytryptamine receptor 3 (5-HT3) as a pharmacodynamic (PD) marker.

Schizophrenia

Cerevance Alpha, Inc.22 participantsStarted Nov 2018

New York, New York, United States • New York, New York, United States • New York, New York, United States

TERMINATEDPhase 2< 1 mile

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Schizophrenia, Schizoaffective Disorder

Hoffmann-La Roche131 participantsStarted Dec 2018

Bellflower, California, United States • Garden Grove, California, United States • Glendale, California, United States +42 more locations

CVN058 Effect on Mismatch Negativity in Schizophrenics

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Schizophrenia Trials in Other Cities

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Using mHealth to Optimize Pharmacotherapy Regimens

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Improving Cognition Via Exercise in Schizophrenia

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Relapse Prevention Study in Patients With Schizophrenia

Adjunctive Vortioxetine in Schizophrenia

Financial Incentives to Improve Medication Adherence

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Relative Bioavailability of LY03010 Compared to Listed Drug

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Other Conditions in New York